市場調査レポート

商品コード

1593452

抗体薬物複合体の市場規模、シェア、成長分析、製品タイプ別、リンカータイプ別、ターゲットタイプ別、ペイロードタイプ別、疾患タイプ別、地域別 - 産業予測、2024年～2031年

Antibody Drug Conjugates Market Size, Share, Growth Analysis, By Product, By Linker Type, By Target Type, By Payload Type, By Disease Type, By Region - Industry Forecast 2024-2031

出版日: 2024年11月12日
発行: SkyQuest
ページ情報: 英文 208 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 760,921円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 890,134円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,019,347円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
目次

概要

サンプル依頼リストに入れる

抗体薬物複合体（ADC）の世界市場規模は2022年に84億1,000万米ドルと評価され、2023年の97億米ドルから2031年には300億9,000万米ドルに成長し、予測期間（2024-2031年）のCAGRは15.2％で成長する見通しです。

世界のがん患者の急増と革新的な医薬品に対する需要の高まりが、今後数年間の抗体薬物複合体（ADC）市場の大幅な成長を促進します。バイオ医薬品研究への投資の増加とADC開発技術の進歩が相まって、市場ダイナミクスはさらに強化されるであろう。さらに、迅速な承認経路の導入により、ADCが市場に到達するまでの時間が大幅に短縮され、予測期間を通じて売上が増加すると予想されます。さらに、個別化医療に向けた動向の高まりとその採用拡大は、ADC市場の開拓を後押しするとみられます。しかし、この分野は、高い開発コスト、毒性に関する安全性の懸念、バイオシミラーとの厳しい競合などの課題に直面しており、ADC企業の世界の成長を妨げる可能性があります。利害関係者がこのような複雑な状況を乗り切る中で、ADC市場は、技術革新と効果的ながん治療に対する緊急のニーズが原動力となる有望な機会を提示しています。

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域

競合情勢

上位5社の比較
主要企業の市場ポジショニング（2023年）
主な市場企業が採用した戦略
市場における最近の活動
主要企業の市場シェア（2023年）

主要企業プロファイル

Roche Holding AG（Switzerland）
Daiichi Sankyo Company, Limited（Japan）
Gilead Sciences, Inc.（US）
Takeda Pharmaceutical Company Limited（Japan）
Pfizer Inc.（US）
Astellas Pharma Inc.（Japan）
AstraZeneca（UK）
ADC Therapeutics SA（Switzerland）
ImmunoGen, Inc.（US）
Zydus Group（India）
AbbVie Inc.（US）
Ambrx（US）
LegoChem Biosciences, Inc.（South Korea）
Byondis（Netherlands）
ProfoundBio（US）
RemeGen（China）
Sutro Biopharma, Inc.（US）
Lepu Biopharma Co., Ltd.（China）
Zymeworks Inc.（Canada）
Mersana Therapeutics（US）
Duality Biologics（China）
Lanova Medicines（China）
Exelixis, Inc.（US）
BioNeCure Therapeutics Inc.（US）
Tripartite Therapeutics, Inc.（US）

Product Code: SQMIG35I2342

Global Antibody Drug Conjugates (ADC) Market size was valued at USD 8.41 billion in 2022 and is poised to grow from USD 9.70 billion in 2023 to USD 30.09 billion by 2031, growing at a CAGR of 15.2% in the forecast period (2024-2031).

The global surge in cancer cases and the rising demand for innovative pharmaceuticals are set to catalyze substantial growth in the antibody drug conjugates (ADCs) market in the coming years. Increased investments in biopharmaceutical research, coupled with advancements in ADC development technologies, will further enhance market dynamics. Moreover, the introduction of expedited approval pathways is expected to significantly reduce the time required for ADCs to reach the market, facilitating increased sales throughout the projected period. Additionally, the growing trend toward personalized medicine and its expanding adoption is likely to support the development of the ADC market. However, the sector faces challenges, including high developmental costs, safety concerns regarding toxicity, as well as stiff competition from biosimilars, which may hinder the growth of ADC companies globally. As stakeholders navigate these complexities, the ADC market presents a promising opportunity driven by innovation and the urgent need for effective cancer therapies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antibody Drug Conjugates (Adc) market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Antibody Drug Conjugates (Adc) Market Segmental Analysis

Global Antibody Drug Conjugates (ADC) Market is segmented on the product, linker type, target type, payload type, disease type, and region. By product, market is segmented into Kadcyla, Enhertu, Adcetris, Padcev, Trodelvy, Polivy, and Other Products. By linker type, market is segmented into Cleavable Linkers and Non-Cleavable Linkers. By target type, market is segmented into HER2, CD22, CD30, and Other Target Types. By payload type, market is segmented into Monomethyl Auristatin E (MMAE), Calicheamicin, Maytansinoids, and Other Payload Types. By disease type, market is segmented into Breast Cancer, Blood Cancer, and Other Disease Types. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Driver of the Global Antibody Drug Conjugates (Adc) Market

The rising global incidence of cancer is a significant market driver for the Global Antibody Drug Conjugates (ADC) market. As cancer continues to pose a formidable public health challenge, there is an escalating demand for innovative and targeted therapeutic options. This urgency has catalyzed extensive oncology research, leading to the development of advanced ADCs that combine the specificity of monoclonal antibodies with potent cytotoxic drugs. Consequently, the growing emphasis on personalized medicine and precise cancer management is expected to significantly enhance the adoption and sales of ADCs, creating robust growth prospects in this specialized therapeutic market segment.

Restraints in the Global Antibody Drug Conjugates (Adc) Market

The Global Antibody Drug Conjugates (ADC) market faces significant restraints due to the high operational costs associated with their manufacturing. The production of ADCs demands specialized equipment, advanced facilities, and a highly skilled workforce, all of which entail substantial capital investment. These elevated costs not only make the production process more expensive but also contribute to higher prices for end products, limiting accessibility and adoption in healthcare settings. Consequently, this financial burden restrains market growth by restricting investment from smaller companies and deterring potential market entrants, ultimately slowing down the overall development and expansion of the ADC market.

Market Trends of the Global Antibody Drug Conjugates (Adc) Market

The global Antibody Drug Conjugates (ADCs) market is witnessing a significant trend towards expanding applications beyond oncology, targeting various chronic diseases to broaden therapeutic horizons. As companies invest in developing ADCs for indications such as autoimmune disorders and infectious diseases, a lucrative landscape is emerging with ample opportunities for innovation. Additionally, the rising demand for combination therapies further propels ADCs into the spotlight, as their ability to enhance efficacy and improve patient outcomes positions them as valuable assets in holistic treatment approaches. This dual advancement is set to drive market growth, creating a dynamic and competitive environment for ADC manufacturers.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Value Chain Analysis
Technology Analysis
Patent Analysis
Pricing Analysis
Customer & Buying Criteria Analysis
PESTEL Analysis

Antibody Drug Conjugates Market, By Product

Market Overview
Kadcyla
Enhertu
Adcetris
Padcev
Trodelvy
Polivy
Other Products

Antibody Drug Conjugates Market, By Linker Type

Market Overview
Cleavable Linkers
Non-Cleavable Linkers

Antibody Drug Conjugates Market, By Target Type

Market Overview
HER2
CD22
CD30
Other Target Types

Antibody Drug Conjugates Market, By Payload Type

Market Overview
Monomethyl Auristatin E
Calicheamicin
Maytansinoids
Other Payload Types

Antibody Drug Conjugates Market, By Disease Type

Market Overview
Breast Cancer
Blood Cancer
Other Disease Types

Antibody Drug Conjugates Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Daiichi Sankyo Company, Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ADC Therapeutics SA (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ImmunoGen, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zydus Group (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ambrx (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
LegoChem Biosciences, Inc. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Byondis (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ProfoundBio (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
RemeGen (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sutro Biopharma, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lepu Biopharma Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zymeworks Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mersana Therapeutics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Duality Biologics (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lanova Medicines (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exelixis, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioNeCure Therapeutics Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tripartite Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

抗体薬物複合体の市場規模、シェア、成長分析、製品タイプ別、リンカータイプ別、ターゲットタイプ別、ペイロードタイプ別、疾患タイプ別、地域別 - 産業予測、2024年～2031年

Antibody Drug Conjugates Market Size, Share, Growth Analysis, By Product, By Linker Type, By Target Type, By Payload Type, By Disease Type, By Region - Industry Forecast 2024-2031

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

抗体薬物複合体市場：製品別

抗体薬物複合体市場：リンカータイプ別

抗体薬物複合体市場：ターゲットタイプ別

抗体薬物複合体市場：ペイロードタイプ別

抗体薬物複合体市場：疾患タイプ別

抗体薬物複合体市場：地域別